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Abstract 
Overexpression of the EVI1 oncogene is associated typically with aggressive 
myeloid leukemia, but is also detectable in breast carcinoma (BC) where its con-
tributions are unexplored. Analyzing a tissue microarray of 608 BC patient spec-
imens, we documented EVI1 overexpression in both estrogen receptor-positive 
(ER+) and estrogen receptor-negative (ER-) BC. Here we report prognostic rele-
vance of EVI1 overexpression in triple-negative BC (TNBC) but not in the HER2-
positive BC subset. In human breast cancer cells, EVI1 silencing reduced prolif-
eration, apoptosis resistance and tumorigenicity, effects rescued by estrogen 
supplementation in ER+ BC cells. Estrogen addition restored ERK phosphoryla-
tion in EVI1-silenced cells, suggesting that EVI1 and estradiol signaling merge in 
MAPK activation. Conversely, EVI1 silencing had no effect on consitutive ERK 
activity in HER2+ BC cells. Microarray analyses revealed G-protein coupled re-
ceptor (GPR) signaling as a prominent EVI1 effector mechanism in BC. Among 
others, the GPR54-ligand KISS1 was identified as a direct transcriptional target 
of EVI1, which together with other EVI1-dependent cell motility factors such as 
RHOJ regulated BC cell migration. Overall, our results establish the oncogenic 
contributions of EVI1 in ER- and HER2-negative subsets of breast cancer.  
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Introduction  
Breast carcinoma (BC) is the most common malignant tumor and predominant 
cause of cancer-related death in women worldwide. During the last years, in-
creasing BC heterogeneity has been documented concerning mutational back-
ground, histopathology, dissemination patterns and efficacy of surgical, anti-
hormonal, chemo- or radiation therapies. Despite high initial remission rates es-
pecially in early stage disease, BC patients carry a significant life-long risk for 
disease relapse (1). Recent research has focused on so-called breast carcinoma 
stem cells (CSCs) as mediators of tumor relapse after long latency (2) as well as 
on stemness proteins as CSC biomarkers and potential drug targets (3,4).  
 
The EVI1 gene is part of the complex MECOM locus on human chromosome 
3q26 and encodes a zinc finger transcription factor that is expressed in long-term 
repopulating hematopoietic stem cells (HSCs) (5,6). In acute myeloid leukemia 
(AML), EVI1 overexpression can occur due to chromosomal rearrangements or 
as a reflection of the stem cell origin of the disease, but in either case predicts 
very adverse prognosis (7). EVI1 expression has been also reported in solid tu-
mors including breast carcinoma (8,9), where it is still largely understudied with 
respect to relevance, functional roles and molecular regulation.  
 
Here we performed a comprehensive expression and functional analysis of EVI1 
in human BC. By analyzing a tissue microarray of 608 patient samples, we found 
high EVI1 protein expression in BC regardless of the ER status. A detailed clini-
 5
co-pathological investigation uncovered a prognostic significance of EVI1 ex-
pression in ER- and especially triple-negative BC, which was however not ob-
served in HER2+ tumor subsets. While EVI1 depletion impaired cell cycle pro-
gression, apoptosis resistance and MAPK signaling in both ER- and ER+ BC 
cells, addition of estrogen could rescue these effects only in ER+ cells. Moreover, 
similar as in patients, HER2 overexpression appeared to overrule EVI1 effects on 
MAPK signaling, explaining why EVI1 expression is of particular clinical rele-
vance in the ER- HER2- tumor subset. Finally, we identified the GPR54-ligand 
KISS1 as a novel transcriptional target of EVI1, which promotes BC cell migra-
tion. In sum, our report identifies EVI1 as an oncogene that profoundly regulates 
BC biology and that is of particular importance for estrogen-independent HER2-
negative tumors.  
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Materials and Methods 
Human tumor samples and tissue microarray (TMA) analysis 
Handling of patient samples and data analyses were performed in accordance 
with federal and state laws and approved by the local ethics committee. The TMA 
included samples from 608 human primary BC (primary or recurrent) histological-
ly processed and diagnosed at the Institute for Pathology and Molecular Patholo-
gy, University Hospital Zurich (Zurich, Switzerland) as described (10). Immuno-
histochemistry using rabbit anti-EVI1 antibodies (Cell Signaling, Danvers, MA) 
and digital expression analysis were performed as published (11). Briefly, a semi-
quantitative image analysis software (Tissue Studio v.2, Definiens AG, Munich, 
Germany) was applied to digitalized TMA slides, obtaining a continuous spectrum 
of average brown staining intensity of tumor cell nuclei in arbitrary units. Subse-
quently, EVI1 expression was categorized in low, medium or high according to 
the 25th and 75th percentile of all measured expression values. Fluorescence in-
situ hybridization (FISH) was used to detect EVI1 copy number gains and rear-
rangements using the EVI1-flanking BAC clones CTD-2079P9 and RP11-
264O10 for probe labeling (12). 
 
Cell lines and culture  
BC cell lines (DSMZ, Braunschweig, Germany) were bought in 2012 and re-
authenticated by DSMZ in September 2014 and August 2015, respectively, using 
a nanoplex PCR for specific DNA profiles in 8 different highly polymorphic short 
tandem repeat (STR) loci. Additionally, samples were tested for the presence of 
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rodent mitochondrial DNA from mouse, rat, chinese and syrian hamster. Cells 
were cultivated according to data sheet. BC primary tissue samples were disso-
ciated to single cells and cultured as described (4). Estradiol (Sigma-Aldrich, St 
Louis, MO), Kisspeptin-10 (Kp-10; Santa Cruz Biotechnology, Dallas, TX) and 
RKI-1447 (Selleckchem, Houston, TX) were used as indicated. 
 
Lentiviral production and transduction 
EVI1-specific or control shRNAs were designed using the MISSION TRC shRNA 
software tool and integrated into the pLKO.1-Puro vector system (Sigma) for len-
tiviral production. EVI1 overexpression and control vectors (13) were kindly pro-
vided by Olga Kustikova and Christopher Baum (Hannover Medical School, Han-
nover, Germany). For inducible overexpression, EVI1 or KISS1 cDNAs (the latter 
cloned from MDA-MB-231 cells using primers as indicated in Supplementary Ta-
ble S2) were integrated into a pLVX vector system to drive expression by 
doxycycline (Sigma) from a Teton lentiviral system (Clontech, Mountain View, CA). 
Lentiviral particles were produced and cells transduced as described (14). 
  
siRNA treatment  
Primary BC cells were cultured for 24 hours with a mixture of 3 independent siR-
NAs against EVI1 and respectively 2 control siRNAs (Life Technologies) together 
with lipofectamine (Invitrogen) in penicillin/streptomycin-free culture medium as 
described (14,15). Cells were then cultured under standard conditions for another 
24 hours and then harvested for mRNA and functional assays. 
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RNA isolation, cDNA synthesis and real-time PCR  
RNA was extracted with an RNeasy kit (Qiagen) and cDNA synthesized using a 
Thermo Script RT-PCR System (Invitrogen). Reverse transcripts were amplified 
by qRT-PCR and quantified upon incorporation of SYBR Green on an ABI 7500 
workstation. Relative expression levels were calculated after normalization to the 
reference gene GAPDH using the ΔΔCT method. CDKN1A, CDKN1B, BIK and 
BBC3 primers were purchased from Qiagen (SYBR® Green QuantiTect Primer 
Assays). Other primer sequences are given in Supplementary Table S2. 
 
Cell growth, cell cycle, proliferation and apoptosis assays 
To assess cell growth, 50.000 cells were plated and quantified after trypsinization 
on days 3, 6 and 9 post-seeding. Cell proliferation was investigated by incorpora-
tion of BrdU or EdU as detailed in the manufacturers’ protocols (BrdU: BD Bio-
sciences, Heidelberg, Germany; Click-iT®, EdU kit: baseclick, Neuried, Germa-
ny). Cell cycle and apoptosis assays were performed as described (15). Cells 
were analyzed by flow cytometry for their DNA content on a FACS Fortessa ma-
chine using FlowJo software (FlowJo enterprise, Ashland, OR). For apoptosis 
assays, 5x104 cells/ml were incubated overnight and then treated either for 16 h 
with staurosporine (2.5 µM; Sigma-Aldrich) or for 24 h with SuperKiller TRAIL™ 
(50 ng/ml; Enzo Life Sciences, Farmingdale, NY).  
 
Immunoblotting  
Immunoblotting was performed as described (4) using the following primary anti-
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bodies (Cell Signaling): anti-pan AKT (#4691S), anti-pAKT (pSer473, #4060S), 
anti-ERK1/2 (#4695), anti-pERK1/2 (Thr202/Tyr204, #4377), anti-GAPDH 
(#5174P), anti-EVI1 (#2593), anti-p21 (#2947), anti-p27 (#3688), anti-CDK2 
(#2546), and anti-β-actin (#3700S). Fluorescently labeled or HRP-conjugated 
secondary antibodies were used as described (14,15). 
 
Microarray gene expression analysis 
Microarrays analyses were performed in triplicates from control and EVI1 knock-
down MDA-MB-231 cells (obtained with either one of two independent EVI1-
specific shRNAs). RNA was extracted with an RNeasy Mini kit (Qiagen). Concen-
tration and purity of RNA samples were determined with a NanoDrop photometer 
(peqlab), and integrity confirmed on a 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA). Only RNA samples with RIN values ≥ 7.5 were considered. Per 
condition, 100 ng of RNA were used to prepare cyanine-3-labeled cRNA for hy-
bridizations, which were performed according to standard protocols using Agilent 
SurePrint G3 Human Gene Expression 8x60K v2 Microarrays. After extensive 
washing, fluorescence intensities were detected with the Scan Control A.8.4.1 
software (Agilent) on an Agilent DNA Microarray Scanner and extracted from im-
ages using Feature Extraction 10.7.31 software (Agilent). Quantile normalization 
was applied to the data set and correlation analysis was performed. Fold change 
calculations identified differentially expressed genes, and Panther analysis most 
prominently affected pathways in EVI1 knockdown vs. control cells. Array data 
will be deposited in the GEO database. 
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Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) was performed as described (16). Briefly, 
1x107 control or EVI1-overexpressing Hs 578T cells were fixed in 1% formalde-
hyde, sonicated, pre-cleared and incubated with 10 μg anti-EVI1 or isotype con-
trol antibodies overnight at 4°C. Complexes were washed, DNA-extracted, pre-
cipitated and amplified by RT-PCR using primers sets homologous to regions of 
the human KISS1 promoter. Non-immunoprecipitated chromatin was used as 
input control. Primers flanking the EVI1-binding site in the BCL2L1 promoter and 
at a previously described non-binding site served as positive and negative con-
trol, respectively (17). 
 
Migration assay 
The established “wound healing assay” was performed to assess cell migration 
(18). Briefly, cells were grown to confluence in 24-well plates and incubated with 
5 μg/ml aphidicolin (Sigma-Aldrich, A4487) and reduced FCS concentrations 
(2%) to stall proliferation. Subsequently, the monolayer was injured with a pipette 
tip and detached cells removed by iterative washing, leaving an approximately 
200-µm wide unsettled zone free for lateral repopulation. Migration into these 
“wound areas” was followed on an Axio Vert.A1 microscope (Zeiss) and quanti-
fied by Fiji Imaging software at 0 h, 12 h and 24 h of incubation with or without 
addition of doxycycline, Kp-10 or RKI-1447 as indicated.  
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Zebrafish xenograft experiments 
Animal experiments and zebrafish husbandry were approved by the “Kantonales 
Veterinaeramt Basel-Stadt”. Xenotransplantation and assessment of tumor cell 
engraftment were performed as described (4,19). In brief, 75 to 100 BC cells la-
beled with the fluorescent CellTracker™ (Life Technologies) were micro-injected 
at 48 h post fertilization into the vessel-free area of the yolk sac of transgenic 
Tg(flk1:eGFP) zebrafish embryos anesthetized in 0.4% tricaine (20). For rescue 
experiments, the fish water was supplemented with 100 nM estradiol (Sigma) or 
carrier (DMSO) at day 0 and 2.5 post transplantation. Tumor development was 
assessed microscopically at day 5 post-injection (19,21). For pERK inhibition, the 
fish water was supplemented with 200 nM of CI-1040 at days 1 and 2 post-
transplantation. 
 
Mouse xenograft experiments 
NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (NSG) mice purchased from Jackson Laboratory 
(Bar Harbor, ME) were maintained under pathogen-free conditions according to 
federal and state regulations. Control and EVI1 knockdown MDA-MB-231 cells 
(1x106) mixed with Matrigel (1:1, BD Biosciences) were co-laterally implanted by 
sub-cutaneous injection into the flanks of individual mice and occurrence of tu-
mors monitored by palpation as reported (15). Tumor area was assessed in situ 
using the Fiji software and tumor weight was measured after excision. 
 
Statistical analyses 
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Unless otherwise indicated, data from ≥3 independent biological experiments 
performed in technical triplicates were analyzed. Results are shown as mean ± 
SD. P-values were calculated by two-tailed, unpaired student’s T-tests or as 
specified and p-values indicated with * for <0.05, ** for <0.01 and *** for <0.001. 
Retrospective survival analyses of BC patients were performed by the Kaplan-
Meier method using log-rank (Mantel–Cox), Breslow and Tarone-Ware tests. 
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Results  
EVI1 gene and protein expression in human breast carcinoma  
First, we assessed EVI1 gene and protein expression in 12 primary human BC 
samples (Fig. 1A) and 8 BC cell lines (Fig. 1B and C; ER-: MDA-MB-231, BT-
549, Hs 578T, MDA-MB-468, SK-BR-3, and ER+: BT-474, T-47D, MCF7). EVI1 
expression was detected in several samples irrespective of the ER status. To 
cover a comprehensive range of endogenous EVI1 expression for subsequent 
functional investigations, two ER- (MDA-MB-231 and Hs 578T) and two ER+ BC 
cell lines (T-47D and MCF7) were chosen and investigated alongside with four 
primary patient-derived cell samples of different ER status (P1-P4).  
 
Furthermore, we employed immunohistochemistry to investigate EVI1 protein 
expression on a tissue microarray (TMA) of 608 BC samples (10). Reliable and 
biologically interpretable results were obtained from 527 samples, in 512 of which 
information on ER status was available. Consistent with our previous data, EVI1 
protein was detected at variable degrees (Fig. 1 D) in both ER- (n=91) as well as 
ER+ (n=421) tumors (Fig. 1D and Supplementary Table S1). However, a signifi-
cant correlation between EVI1 expression levels and survival was only observed 
in the ER- subgroup (n=91 patients; 5-year survival: p=0.011, overall survival: 
p=0.026) but not in the ER+ subgroup (n=421 patients) or the whole patient co-
hort analyzed together (Supplementary Fig. S1A). Interestingly, the influence of 
EVI1 expression on overall survival was most pronounced in triple-negative BC 
(p=0.006), but lost when ER-/HER2+ subsets were separately analyzed (Sup-
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plementary Fig. S1A). Together, these data suggest that EVI1 expression is of 
particular significance in BC that is not driven by active ER and HER2 signaling.  
 
ER- and triple-negative BC subgroups, in which EVI1 showed prognostic rele-
vance, were subjected to further analysis of clinico-pathological parameters. High 
EVI1 expression associated indeed with enhanced distant metastasis rate 
(p=0.046 and p=0.027, respectively; Supplementary Fig. S1A), indicating a puta-
tive functional contribution to tumor cell dissemination/migration. To investigate 
the mechanisms responsible for EVI1 overexpression, we performed FISH anal-
yses. Unlike in leukemia (22), we could not detect EVI1 gene rearrangements or 
copy number gains except in two out of 512 BC patients (Fig. 1E, Supplementary 
Fig. S1B).  
 
Based on these data we conclude that EVI1 expression is frequently observed in 
human BC, where it is mostly driven by yet unknown regulatory events, and 
might be particularly relevant for estrogen-independent HER2-negative tumors. 
 
EVI1 induces cell proliferation and apoptosis resistance 
To examine the functional significance of EVI1 in BC, we performed EVI1 knock-
down experiments in two ER- (MDA-MB-231 and Hs 578T) and one ER+ (T-47D) 
BC cell line and two patient-derived primary BC samples per condition (ER+: P1, 
P2; ER-: P3, P4). Cells were transduced with lentiviral particles carrying either 
non-coding or two alternate EVI1 shRNAs. Transduction with either shRNA 
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down-regulated EVI1 protein and mRNA expression when compared to controls 
(Fig. 2A, Supplementary Fig. S2A-B and S3A). Throughout all analyzed samples, 
EVI1 knockdown cells showed a clear growth defect when compared to corre-
sponding control cells (Fig. 2B, Supplementary Fig. S2C and S3B).  
 
The lower growth rates observed in EVI1 knockdown cells could be caused by 
decreased proliferation or enhanced apoptosis rates, both of which are modulat-
ed by EVI1 in other cell types (22). Indeed, knockdown of EVI1 enhanced basal 
BC cell apoptosis (Fig. 3A, Supplementary Fig. S2D and Fig. S3C) as well as 
apoptosis sensitivity in response to staurosporine or the death ligand TRAIL (Fig. 
3B, Supplementary Fig. S3D). In addition, cell cycle analyses revealed a G1 to S 
phase transition defect upon EVI1 knockdown (Fig. 3C, Supplementary Fig. S3E) 
indicating a proliferation defect. Supporting this notion, BrdU incorporation was 
also diminished (Fig. 3D, Supplementary Fig. S3F). In line, key checkpoint regu-
lators that block G1 to S phase transition, such as the cyclin-dependent kinase 
inhibitors 1A and 1B (p21Cip1 and p27Kip1) were up-regulated in EVI1 knockdown 
MDA-MB-231 cells, while their mutual downstream target CDK2 was decreased 
(Supplementary Fig. S4).  
 
Stimulation of the ER pathway rescues pERK expression and growth in 
EVI1 knockdown BC cells 
Intriguingly, the profound growth-modulatory effects of EVI1 were observed inde-
pendent of the ER status, which is in apparent contrast to the prognostic signifi-
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cance of EVI1 expression especially in ER- BC patients. Indeed, the in vitro find-
ings in ER+ BC cells could be biased by lack or reduced ER stimulation under 
standard cultivation conditions. Confirming this hypothesis, addition of estradiol 
greatly restored growth of EVI1 knockdown ER+ T-47D but not ER- MDA-MB-
231 BC cells (Fig. 4A). Consistently, estradiol fostered the incorporation of EdU in 
T-47D but not in MDA-MB-231 EVI1 knockdown cells (Fig. 4B). We conclude that 
active estrogen signaling overrules EVI1-mediated growth effects and, therefore, 
EVI1-mediated growth induction may be more critical for patients with ER- tu-
mors that do not equally respond to natural estrogen. 
 
ERK and AKT kinases are key regulators of cell proliferation and survival down-
stream of estrogen signaling (23-25). We thus wondered whether EVI1 also acts 
via activation of these kinases in BC. No consistent pAKT suppression was ob-
served in EVI1 knockdown cells (Fig. 4C and 4F), although EVI1 overexpression 
indeed induced pAKT levels (Fig. 4D). However, an overt decrease in phosphory-
lated (i.e. activated) ERK levels was reproducibly noted upon EVI1 knockdown 
throughout the analyzed ER- and ER+ BC samples (Fig. 4C and Supplementary 
Fig. S5A), indicating the ERK pathway as a dominant growth axis regulated by 
EVI1. Indeed, treatment with MEK inhibitors (CI-1040, trametinib or AZD6244) 
that act upstream of ERK (26) similarly suppressed cell growth and cycle pro-
gression of MDA-MB-231 and T-47D cells (Supplementary Fig. S5B-F). Further 
supporting this notion, addition of estradiol enhanced ERK but not AKT phos-
phorylation in EVI1 knockdown ER+ T-47D but not ER- MDA-MB-231 BC cells 
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(Fig. 4C). EVI1 overexpression consistently up-regulated pERK in MCF7, T-47D 
and MDA-MB-468 cells, and displayed synergistic effects with estradiol in ER+ T-
47D cells (Fig. 4D-E). Interestingly, the rescue of cell growth induced by β-
estradiol in EVI1 knockdown cells was abrogated by co-treatment with either the 
ER blocking reagent tamoxifen or the MEK inhibitor CI-1040 (Supplementary Fig. 
S5G). 
 
As also HER2 mediates growth-stimulatory effects via the MAPK/ERK signaling 
axis in BC, we further examined the significance of EVI1 knockdown on HER-
dependent ERK phosphorylation and found that, while loss of EVI1 signaling ef-
fectively depleted pERK in HER2- BC cells, ERK phosphorylation remained es-
sentially unaltered in the investigated HER2+ samples (Fig. 4F, left vs. right pan-
els). Together, these data suggest that EVI1, ER, and HER2 signaling functional-
ly impinge on phosphor-modulation of ERK as a common downstream pathway. 
 
EVI1 knockdown suppresses tumor formation in vivo  
Next, we used xenotransplantation assays to examine the relevance of EVI1 for 
in vivo tumorigenesis from human BC cells. Equal numbers of EVI1 knockdown 
and control MDA-MB-231 cells (ER-HER2-) were injected subcutaneously into 
contralateral flanks of immuno-permissive NSG mice and tumor formation was 
assayed over time. At 12 days post-transplantation, smaller tumors were docu-
mented from EVI1 knockdown cells versus control cells (Fig. 5A-C), indicating 
that EVI1 influences in vivo tumorigenicity. Immunoblot analysis confirmed per-
 18
sistent knockdown of EVI1 and impaired phosphorylation of ERK in excised tu-
mors (Supplementary Fig. S6A). These data where confirmed in a previously es-
tablished zebrafish xenotransplant model (4,19). Consistent with the results ob-
tained in mouse, both EVI1 knockdown ER+ T-47D and ER- MDA-MB-231 cells 
induced fewer tumors than corresponding control cells, while estrogen supple-
mentation rescued in vivo tumor formation selectively from ER+ cells (Fig. 5D-E, 
Supplementary Fig. S6B). Moreover, the MEK inhibitor CI-1040 was able to block 
the rescue effect of β-estradiol in vivo (Supplementary Fig. S6C). In line with their 
reduced in vivo tumorigenicity, EVI1 knockdown cells also displayed impaired 
mammosphere formation in vitro (Supplementary Fig. S6D). These data indicate 
that, although EVI1 may not be a specific CSC marker in BC, it co-regulates the 
stem cell compartment.  
 
Identification of GPCR signaling-associated molecules as EVI1 downstream 
targets 
To further explore the molecular mechanisms underlying EVI1-driven effects in 
BC, we analyzed the transcriptome of control and EVI1 knockdown MDA-MB-231 
cells using gene expression microarrays. 816 differentially expressed genes were 
identified in EVI1 knockdown versus control cells, of which 324 were up- and 492 
down-regulated. Panther analysis identified cell(-cell) adhesion, cell communica-
tion, signal transduction, developmental and immune system process regulation 
as the predominantly influenced biological processes, and receptors, cell-
adhesion and respectively extracellular matrix proteins as the most significantly 
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affected protein classes (Fig. 6A). Furthermore, GeneSpring analyses revealed 
“G protein–coupled receptor (GPCR) signaling” molecules such as KISS1, EDN1, 
PTGFR and PIK3CG (Fig. 6B-C) as the most influenced pathway, next to cell-
cycle control and progression (with perturbed expression levels of several key 
regulators such as CDKN1A, CDKN1C, CCNA1 and CDK1), apoptosis re-
sistance (with up-regulation of pro-apoptotic genes such as BIK, BMF, and 
BBC3) and ERBB signaling-related molecules (e.g. EREG, DUSP5, and NRG2). 
Heat maps of these individual categories are depicted in Fig. 6C and Supplemen-
tary Fig. S7A-B with a cut-off of 2-fold and 1.5-fold expression changes, respec-
tively. EVI1-dependent expression changes of 15 exemplary candidate genes 
were further validated by qRT-PCR (Supplementary Fig. S7C). 
 
To identify potential direct target genes of EVI1 in BC, we next investigated the 
expression of candidate genes in response to EVI1 overexpression (Supplemen-
tary Fig. S7D). Among these, the GPR54-ligand KISS1 stood out as one of the 
most strongly influenced genes. Additionally, the induction of KISS1 mRNA dis-
played a clear dose-dependency on EVI1 transcript levels (Fig. 7A). Furthermore, 
co-depletion of EVI1 and KISS1 mRNA was observed in primary BC cells treated 
with siRNAs against EVI1 versus corresponding control siRNA-treated cells 
(Supplementary Fig. S7E). Moreover, promoter analysis of KISS1 revealed sev-
eral potential EVI1-binding sites within KISS1 regulatory elements (Supplemen-
tary Fig. S8A), reinforcing KISS1 as a putative direct transcriptional target of 
EVI1. Based on this analysis, four promoter regions of KISS1 were selected 
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(Supplementary Fig. S8A) and assessed for EVI1 binding in chromatin immuno-
precipitation (ChIP) assays. Higher enrichment rates were indeed observed in 
EVI1-overexpressing vs. control cells especially at the most distal promoter site (-
4880 to -4761 bp, Fig. 7B). Thus, these data identify the KISS1 promoter as a yet 
unrecognized target region for EVI1 in BC (see also Supplementary Fig. S8 for 
control and schematic illustration of binding sites). We therefore conclude that, 
next to modulating expression of cell cycle- and apoptosis-relevant genes (Fig. 
6B-C and Supplementary Fig. S7B-C), EVI1 directly influences GPCR signaling 
via transcriptional modulation of the GPR54 ligand KISS1. 
 
Differential role of KISS1 in EVI1-mediated cell migration, cell growth and 
ERK activation 
KISS1 was originally identified as a metastasis suppressor (27,28), and more 
recently described to enhance motility and invasiveness of ER- BC cells (29,30). 
We thus hypothesized that EVI1 contributes to these processes at least in part 
via transcriptional regulation of KISS1. Indeed, migration assays revealed that 
knockdown of EVI1 strongly impaired the motility of ER- MDA-MB-231 (Fig. 7C-
F) and Hs 578T cells (Supplementary Fig. S9A-B), whereas overexpression of 
EVI1 overtly increased cell mobility (Fig. 7G-H, Supplementary Fig. S9C-D). 
Supporting the role of KISS1 as a downstream target in EVI1-dependent migra-
tion, exposure of cells to the GPR54-ligand Kisspeptin-10 (Kp-10), a gene prod-
uct of KISS1 shown to enhance ER- BC cell motility (Supplementary Fig. S10A), 
indeed rescued the migration defects observed in EVI1 knockdown MDA-MB-231 
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cells (Fig. 7C-D). Supporting these data, overexpression of KISS1 itself also res-
cued migration in EVI1 knockdown MDA-MB-231 (Supplemental Fig. S10A-B 
and Fig. 7E-F) and Hs 578T cells (Supplemental Fig. S9A-B).  
 
Noteworthy, several further modulators of cell motility and adhesion were found 
to be regulated by EVI1 in our microarray analysis, including e.g. RhoJ and TIE1, 
two molecules that had not been linked to EVI1 or BC cell migration before. Ex-
emplifying the functional relevance of also these findings, inhibition of 
RHO/ROCK signaling with RKI-1447 impaired EVI1-induced BC cell mobility in 
migration assays (Fig. 7G-H and Supplementary Fig. S9C-D). 
 
Interestingly, supplementation with Kisspeptin (Kp-10), which effectively rescued 
migration (Figure 7C-D), could not restore cell growth in EVI1 knockdown cells 
(Supplementary Fig. S10C). Consistently, neither treatment with Kisspeptin (Kp-
10) nor KISS1 overexpression influenced pERK activity (Supplementary Fig. 
S10D). Vice versa, treatment of BC cells with the MAPK inhibitor CI-1040 effec-
tively suppressed pERK and cell growth (Supplementary Fig. S5F and Supple-
mentary Fig. S5B-C) but did not influence BC cell migration (Supplementary Fig. 
S10F-G). In particular, treatment with CI-1040 did not abrogate EVI1-induced 
KISS1 overexpression (Supplementary Fig. S10E) and related BC cell migration, 
reinforcing the idea that these effects are independent of the MAPK pathway 
(Fig. 7I). 
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Taken together, we demonstrate a functional relevance of EVI1 gene expression 
for BC cell growth that involves modulation of pERK signaling (see Fig. 7I for 
schematic illustration). In part complementary to ER signaling and eventually 
overruled by constitutive ERK activity in HER2+ BC, EVI1-mediated effects 
achieve pivotal significance in ER- HER2- BC, where EVI1 expression is of prog-
nostic significance. Moreover, we present evidence for a hitherto unrecognized 
EVI1-KISS1-GPR54 axis that – independently of ERK signaling – modulates BC 
cell motility, suggesting that also the capacity to induce metastasis may be inti-
mately linked to EVI1. Thus, our work identifies EVI1 as a novel critical determi-
nant of BC cell biology that is of particular importance for estrogen-independent 
HER2- BC.  
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Discussion 
Initially identified as a retroviral insertion region in hematopoietic cells (31), EVI1 
has been intensely studied in HSCs and AML where it represents a marker of 
adverse prognosis. EVI1 is also expressed in other tissues such as brain, lung, 
and kidney (32-34). Pointing towards its significance in early organogenesis, Evi1 
knockout mice are embryonically lethal and show broad hypocellularity and pat-
terning defects (35,36). The molecular regulation and functional relevance of 
EVI1 expression in BC however are largely unexplored. 
 
Analysis of a large cohort of primary samples did not detect significant gene rear-
rangements or copy number gains, indicating that activation of the EVI1 locus in 
BC follows different principles than in myeloid leukemia, such as regulation via 
miRNAs (8). Consistently, a common EVI1 polymorphism (rs6774494 A>G) tar-
geted by miR-206/133b was suggested to predict adverse outcome in post-
menopausal BC patients (37). Interestingly, immunohistochemical analyses of 
our patient cohort identified EVI1 protein as a prognostic marker in ER- but not 
ER+ BC, supporting previous mRNA-based studies (8,38). Importantly, when the 
ER- cohort was further subdivided in ER-HER2+ and triple-negative BC, EVI1 
expression influenced survival specifically in the latter. In this subgroup, high 
EVI1 expression further associated with enhanced distant metastases.  
 
Functional studies documented a profound growth defect in EVI1 knockdown 
versus control cells, resulting from impaired proliferation, cell cycle progression 
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and apoptosis resistance. Interestingly, addition of estrogen to ER+ but not ER- 
cells restored the impaired ERK activation and proliferation. Furthermore, both 
effects of β-estradiol were abrogated by co-treatment with either the ER blocking 
reagent tamoxifen or the MAPK inhibitor CI-1040, which highlights the specificity 
of the observed effects and indicates that EVI1 and β-estradiol merge in pERK 
activation to regulate BC cell growth. However, an inverse correlation was docu-
mented between EVI1 expression and tumor size in triple-negative BC and by 
trend also in the ER- subgroup. We hypothesize that the subgroup of BC pre-
senting with large primary tumor size and negative to low EVI1 expression is 
driven by aggressive, yet EVI1-unrelated molecular mechanisms. 
 
Our analyses reliably identified the significance of EVI1 expression in the ab-
sence of endogenous estrogen signaling. In contrast, in the ER+ BC cohort such 
analyses might be complicated by the fact that these patients receive anti-
estrogen treatments. The importance of EVI1 expression might differ depending 
on the patient response and efficacy of such treatments. Our functional data 
show that EVI1 also severely regulates the growth of ER+ BC cells, if estrogen is 
not provided. Unfortunately, we have no detailed and complete information on the 
mode and efficacy of anti-estrogen treatments of the ER+ BC patients. Thus, 
while our analyses support the notion that EVI1 could impact BC independently 
of ER signaling, assessment of the relevance of EVI1 in ER+ BC requires further 
patient stratification according to the response to anti-estrogen treatment. 
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Suppression of EVI1 expression consistently inhibited MAPK activation in HER2- 
but not HER2+ BC. Thus, potential inhibitory effects of EVI1 knockdown on 
MAPK signaling might be overruled by constitutive HER2 activity. This assump-
tion is consistent with the results in patients where EVI1 expression levels were 
prognostically relevant in triple-negative BC, but not in ER- HER2+ subsets. 
Thus, EVI1, estrogen and HER2 signaling might converge on MAPK signaling as 
a common downstream effector controlling BC cell growth. Growth-stimulatory 
properties of estrogen in BC also involve transcriptional induction of cyclin D1 
(39) and suppression of CDK inhibitors, such as p21Cip1 or p27Kip1 (40). Indeed, 
our investigations uncovered that also these growth-regulatory events are influ-
enced by EVI1 and, moreover, that EVI1 modulates the expression of several 
further key cell cycle regulators (e.g. CDKN1A, CDKN1B, CDKN1C, CCNA1 and 
CDK1).  
 
In addition, our data suggest that EVI1 enhances apoptosis resistance in BC by 
inducing a concerted suppression of pro- and induction of anti-apoptotic genes. 
In line with previous data (14,17), we found a physical association of EVI1 with 
the BCL-XL promoter. Previous links between EVI1 and apoptosis include direct 
blocking interactions with JNK in hematopoietic cells, and the inhibition of apop-
tosis through a PI3K-dependent mechanism in colon cancer cells (41,42). EVI1 is 
further discussed as a stem cell factor in hematopoiesis and leukemia (22), but in 
BC it rather homogenously marked tumor cells, at least in cases of high EVI1 
expression. Nevertheless, EVI1 knockdown impacted the frequency of in vivo 
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tumor- as well as in vitro mammosphere-initiating BC cells. These data suggest 
that, even though not confined to breast CSCs, EVI1 expression might also regu-
late this compartment. 
 
Intriguingly, we identified migration as a novel cellular function promoted by EVI1 
in BC. In particular, EVI1 knockdown impaired the BC cell mobility, whereas its 
overexpression enhanced migration. Gene microarray and qRT-PCR experi-
ments surprisingly uncovered, next to regulators of cell cycle and apoptosis, sev-
eral factors implicated in cell communication and GPCR signaling as downstream 
effectors of EVI1. Of these, we analyzed in more detailed the GPR54-ligand 
KISS1, which ChIP assays identified as a novel transcriptional target of EVI1. 
The EVI1-KISS1 ligand axis promoted motility of ER- BC cells, in line with previ-
ously reported roles of KISS1 on mobility and adhesion in this disease entity 
(29,30). Interestingly, although KISS1 has been reported as an upstream regula-
tor of ERK (43), stimulation with the GPR54-ligand Kp-10 was not able to restore 
pERK and proliferation of EVI1 knockdown BC cells, although it did influence BC 
cell migration. Vice versa, MAPK inhibition effectively suppressed cell growth but 
did not alter migration, again reinforcing the idea that the EVI1-KISS1 migratory 
axis acts independently of pERK. Besides KISS1, we identified additional estab-
lished (e.g. CXCR4, CCR1, AKAP12) (44-46) as well as novel factors in BC cell 
migration as targets of EVI1. For instance, TIE1, a modulator of angiogenesis 
and cell adhesion (47), and RhoJ, a modulator of the RHO/ROCK-dependent cell 
motility (48), were found to be modulated by EVI1, suggesting that this transcrip-
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tion factor serves as a master regulator of BC cell motility. 
 
Taken together, our data identify EVI1 as a potent oncoprotein regulating BC cell 
proliferation, apoptosis resistance and migration. Interestingly, estrogen and 
HER2 signaling as well as EVI1-mediated transcriptional modulation seemingly 
merge to stimulate MAPK signaling. This functional convergence identifies EVI1 
as a major driver of cell growth acting independently of estrogen signaling. EVI1 
and downstream MAPK activation might represent therapeutic targets in patients 
suffering from HER2- ER- or ER+ BC resistant to anti-estrogen therapies. Finally, 
targeting the newly identified EVI1-GPR54-KISS1 axis, for example by GPR54 
inhibitors, may be considered for the treatment of metastasizing ER- BC. Effec-
tive targeting of EVI1-induced BC cell migration might however require either in-
hibition of EVI1 itself or joint suppression of additional migratory pathways (e.g. 
RHO/ROCK signaling). 
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Figure legends 
 
Figure 1: Differential expression of EVI1 in human BC cells. A, qRT-PCR analy-
sis of EVI1 expression in 12 primary BC samples and B, 8 BC cell lines. Indicat-
ed are EVI1 expression levels relative to MDA-MB-231 cells (dotted line); mid-
line illustrates average expression (A). C, Immunoblots documenting variable 
degrees of EVI1 protein expression in ER+ and ER- BC cell lines. Predominant 
isoforms (MDS/EVI1, EVI1, and EVI1Δ) are indicated. Beta-actin is shown for 
loading control. D, Immunohistological image sections illustrating different de-
grees (weak, medium, strong) of EVI1 expression in BC TMA samples. Overview 
pictures (bottom, scale bars = 100 µM), inlays at higher magnification (top). E, 
Representative FISH analysis showing normal distribution of EVI1 copy numbers 
in BC. Red and green FISH probes, respectively, flank the EVI1 gene locus. Nu-
cleus (DAPI, blue). 
 
Figure 2: EVI1 promotes BC cell growth in vitro. A, Immunoblot and qRT-PCR 
analyses documenting efficient depletion of EVI1 expression in EVI1 knockdown 
versus control BC cell lines and primary patient-derived cell samples. ER- (MDA-
MB-231, P3 and P4, left), ER+ (T-47D, P1 and P2, right). Due to low protein lev-
els in patient sample P4, depletion of EVI1 expression was confirmed by RT-
PCR. B, Growth curves illustrating a proliferation defect in EVI1 knockdown vs. 
control cells. ER- cells (left), ER+ cells (right). Plotted are mean values ± SD.  
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Figure 3: EVI1 affects apoptosis regulation and cell cycle progression in BC. 
EVI1 knockdown MDA-MB-231 (left panels) and T-47D cells (right panels) reveal 
A, elevated basal apoptosis; B, increased apoptosis sensitivity in response to 
TRAIL and staurosporine; C, increased cell cycle arrest and D, reduced BrdU 
incorporation compared to control shRNA-treated cells. Shown are mean values 
± SD.  
 
Figure 4: EVI1 synergizes with estrogen and HER2 signaling in the activation of 
MAPK/ERK. A, Growth curves, B, EdU incorporation and C, immunoblots of 
pERK and pAKT performed on EVI1 knockdown versus control MDA-MB-231 
and T-47D cell lines propagated in the absence or presence of estradiol (100 
nM). D, Immunoblot analyses showing increased pERK and pAKT levels in EVI1 
overexpressing versus control MCF7, T-47D and MDA-MB-468 BC cells grown in 
the absence or presence of estradiol. E, EVI1 and estradiol synergize in the in-
duction of pERK in T-47D cells. F, Knockdown of EVI1 expression depletes 
pERK from HER2- BC cells (MDA-MB-231, patient samples P3 and P4, left), but 
not from HER2+ cells (SKBR3, patient samples P1 and P5, right).  
 
Figure 5: EVI1 knockdown impairs tumor growth in vivo. A, ER- MDA-MB-231 
control (right) and EVI1 knockdown cells (left) were contra-laterally injected sub-
cutaneously into NSG mice. Illustrated is a representative example of tumor for-
mation after a follow-up of 12 days. Note that EVI1 knockdown cells generate 
smaller tumors (left). B/C, Corresponding quantitative analysis of tumor area and 
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tumor masses (n=5). P-values were calculated by a Mann-Whitney test. D, 75-
100 CM-DiI-labeled control or EVI1 knockdown BC cells were transplanted into 
the yolk sac of Tg(kdrl:eGFP) fish embryos and analyzed at day 5 post-
transplantation by confocal microscopy for tumor formation (red). E, estradiol 
treatment (100 nM estradiol, 3 days pre-treatment of cells in vitro and afterwards 
added to the fish water) restores reduction of tumor formation upon EVI1 knock-
down in ER+ T-47D cells. 
 
Figure 6: Gene expression patterns associated with EVI1 knockdown. A, Pan-
ther classification linking gene signatures from EVI1 knockdown transcriptome 
analysis to Biological Process and Protein Classes. Significantly modulated 
gene/protein classes are indicated. B, Index list of pathways significantly modu-
lated by EVI1 knockdown (i.e. p<0.05). C, Heat-maps depicting 24 individual 
gene entries whose expression significantly differs in a microarray analysis of 
control vs. EVI1 knockdown MDA-MB-231 cells. Genes most strongly affected by 
EVI1 knockdown functionally cluster in the categories cell cycle regulation, apop-
tosis, GPCR and ERBB signaling.  
 
Figure 7: EVI1 regulates BC cell migration via modulation of GPR54/KISS1 and 
RHO/ROCK signaling. A, qRT-PCR analyses documenting dose-dependent co-
induction of EVI1 and KISS1 in inducible EVI1-overexpressing T-47D cells. B, 
ChIP analysis illustrating direct recruitment of EVI1 to regulatory KISS1 promoter 
elements in Hs 578T control and more strongly in EVI1-overexpressing cells. C-F, 
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Supplementation with the soluble KISS1 gene product Kp-10 (1 µM, C-D), or 
overexpression of KISS1 itself (E-F) ameliorates migration defects imposed by 
EVI1 knockdown in MDA-MB-231 BC cells. Overview images (left), correspond-
ing assay quantifications (right). G-H, Migration assays documenting increased 
mobility of MDA-MB-231 cells in response to EVI1 overexpression, whereas 
treatment with the RHO/ROCK pathway inhibitor RKI-1447 impairs the mobility of 
EVI1-overexpressing MDA-MB-231 cells. Image sections (G, left), corresponding 
assay quantification (H, right). I, Integrated scheme of EVI1-dependent signaling 
pathways influencing BC cell migration and growth.  
 
 
 
 







